A randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of intracoronary NITRITE infusion during Acute Myocardial Infarction
| ISRCTN | ISRCTN38736987 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN38736987 |
| EudraCT/CTIS number | 2011-000721-77 |
| ClinicalTrials.gov number | NCT01584453 |
| Secondary identifying numbers | 12117 |
- Submission date
- 18/01/2013
- Registration date
- 23/01/2013
- Last edited
- 27/08/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Anthony Mathur
Scientific
Scientific
London Chest Hospital
Victoria Park Site
Bonner Road
London
E2 9JX
United Kingdom
| a.mathur@qmul.ac.uk |
Study information
| Study design | Randomised single centre double-blind placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | A randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of intracoronary NITRITE infusion during Acute Myocardial Infarction |
| Study acronym | NITRITE-AMI |
| Study objectives | Despite advances in the treatment of heart attacks such as reopening of the blocked artery (primary angioplasty), the complications and death rates from failure of the heart to pump adequately remain high. The size of the heart attack is the major determinant of these adverse outcomes. Whilst reopening the artery allows blood to flow to the area of the heart starved of oxygen, this process also causes damage itself (reperfusion injury) and increases the size of the heart attack. It has been shown that nitrite protects against reperfusion injury in models of heart attack. We will therefore perform a trial to investigate whether during a heart attack, an infusion of nitrite into the damaged artery protects against reperfusion injury and reduces heart attack size. More details can be found at: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=12117 |
| Ethics approval(s) | Committee:- NRES Committee London-West London, 08 November 2011, REC reference: 11/LO/1500 |
| Health condition(s) or problem(s) studied | Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Atherothrombosis |
| Intervention | Sodium Chloride, Placebo 10mls Intra-coronary at time of PPCI; Sodium Nitrite, Study IMP 10mls 1.8% intra-coronary during PPCI The experimental intervention is a bolus of sodium nitrite solution (1.8 micromol in 10 ml (pre-diluted in 0.9% sodium chloride in a syringe) which will be delivered over 30 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI. The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite). |
| Intervention type | Other |
| Primary outcome measure | Creatine Kinase AUC first 48 hours after PPCI |
| Secondary outcome measures | 1. Infarct size on CMR; Timepoint(s): 48 hours and 6 months 2. Myocardial salvage index (MSI) on CMR; Timepoint(s): 48 hours 3. Troponin T AUC; Timepoint(s): 1st 48 hours after PPCI |
| Overall study start date | 10/04/2012 |
| Completion date | 10/02/2014 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | UK Sample Size: 80 |
| Key inclusion criteria | 1. Patients aged at least 18 years, upper age limit 80 years, male and female 2. Acute ST-elevation myocardial infarction with ECG showing at least 2 mm of ST segment elevation in 2 or more limb leads or 1mm in 2 or more contiguous chest leads, or new left bundle branch block 3. Haemodynamically stable 4. Estimated symptom to balloon or aspiration time < 6 hours 5. A signed and dated written informed consent prior to admission to the study 6. Angiographicallly 6.1. Primary Percutaneous Coronary Intervention (PPCI) indicated for revascularisation 6.2. Single epicardial artery to be treated 6.3. Expected ability to use the over the wire balloon for delivery of nitrite |
| Key exclusion criteria | 1. Patients already on nitrate Treatment (Nicorandil, ISMN) 2. Previous history of myocardial infarction (MI) or systolic dysfunction 3. Previous coronary artery bypass surgery (CABG) 4. Subjects presenting with cardiogenic shock (SBP <80 mmHg for >30 minutes, or requiring inotropes or emergency IntraAortic Balloon Pump (IABP) for hypotension treatment) or cardiopulmonary resuscitation 5. Current diagnosis of or treatment for malignancy, other than non-melanoma skin cancer 6. Current life-threatening condition other than vascular disease that may prevent a subject completing the study 7. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication 8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subjects unwillingness to comply with all study-related procedures) 9. Severe acute infection, or significant trauma (burns, fractures) 10. Pregnancy 11. Contraindications tocardiac magnetic resonance (CMR) scanning 11.1. Pacemakers, intracranial clips or other metal implants or foreign bodies 11.2. Claustrophobia 11.3. Renal Failure (eGFR<30mls/min) 12. History of alcohol or drug abuse within the past 6 months 13. History of congenital methaemoglobinaemia 14. Angiographically 14.1. Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the over the wire balloon |
| Date of first enrolment | 10/04/2012 |
| Date of final enrolment | 10/02/2014 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
London Chest Hospital
London
E2 9JX
United Kingdom
E2 9JX
United Kingdom
Sponsor information
Barts and The London NHS Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Joint Research Office
24-26 Walden Street
London
E1 2AN
England
United Kingdom
| Website | http://www.bartsandthelondon.nhs.uk/ |
|---|---|
"ROR" |
https://ror.org/00b31g692 |
Funders
Funder type
Government
NIHR (UK) - Doctoral Research Fellowship; Grant Codes: NIHR-DRF-2011-04-080
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 02/04/2013 | Yes | No | |
| Results article | results | 01/04/2017 | Yes | No | |
| Results article | results | 30/01/2015 | 27/08/2019 | Yes | No |
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
27/08/2019: ClinicalTrials.gov number added. Publication reference added.
25/09/2018: Publication reference added.
